Showing results (261-270 of 304) with videos related to
Sort By:
Pageof 31
Journal of the European Academy of Dermatology and Venereology : JEADV|October 5, 2022
Amelanotic/hypomelanotic lentigo maligna: Dermoscopic and confocal features predicting diagnosisMaria A Pizzichetta, Jerry Polesel, Jean L Perrot, et al.Cancers|April 3, 2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Mario Giuliano, Fabiola Giudici, et al.The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.EMBO Molecular Medicine|April 24, 2024
Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancerAlice Gambelli, Anna Nespolo, Gian Luca Rampioni Vinciguerra, et al.Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.Tumori|October 13, 2011
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)Stefania Gori, Massimo Di Maio, Carmine Pinto, et al.Lancet (London, England)|March 6, 2015
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Sabino De Placido, Paolo Bruzzi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.Scientific Reports|April 26, 2020
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosisLorenzo Gerratana, Debora Basile, Barbara Toffoletto, et al.Tumori|April 4, 2013
Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM)Stefania Gori, Massimo Di Maio, Carmine Pinto, et al.Pageof 31